With targeted therapies and cancer immunotherapies emerging, how are payers managing the costs of treating cancer while providing uncompromised medical care?
Clinical outcomes in many cancer types are typically thought to be quite dire. However, things are now changing for the better due to the growth of targeted therapies and cancer immunotherapies, but healthcare systems are struggling to afford the costs. Now, a top priority in oncology is overcoming market access challenges of expensive but valuable cancer treatments. Learn more about weighing value versus affordability in oncology and the value frameworks that affect the decision-making process.